According to the Indian Council of Medical Research - National Cancer Registry Programme (ICMR-NCRP), India reports about 220,000 new cases every year, and the common treatment procedure for this disease is chemotherapy, which comes with profound fatigue, hair loss, nausea, compromised immunity, and nerve damage.The University College London led the Optima trial, which studied over 4000 patients with the disease in different parts of the world, and a low score on the genomic test could be mediated with only hormone therapy. The trial’s chief investigator and a professor of breast oncology at UCL, Professor Rob Stein, explains that the study used tumour biology to guide decisions instead of relying on traditional clinical procedures. The research had 4,429 women participants above the age of 40 years with hormone-positive breast cancer. These patients were then divided into two groups based on the genomic test results by the researchers, and one group with a higher risk was given chemotherapy along with hormone therapy, while the others were only treated with hormone therapy.What Is Breast Cancer?Breast cancer refers to the uncontrolled growth of the cells that are found along the inner lining of breast tissue. This out-of-control growth of cells leads to the formation of tumours. The tumour can be “invasive”, meaning that it spreads to the nearby tissues outside the breast, or “in situ”, where the tumour does not spread outside the breast region.Usually, the “in situ” type of tumour is non-cancerous and non-life-threatening. However, in the case of invasive tumours, the cancerous cell mass can spread to the lymph nodes and further metastasise, that is, spread to other body parts. About 80% times the breast cancer cases are invasive. Hence, upon noticing symptoms like lumps, changes in breast shape, or abnormal nipple discharge, you must promptly consult a doctor.While both men and women can develop it, in 99% of cases of breast cancer, women are seen to be affected by it. Only 0.5 to 1% of men are affected due to this condition. Furthermore, the condition is mostly prevalent in women aged 50 or older.